AI-generated research brief — verify at source
Evolocumab Cuts First Major Cardiovascular Events by 31% in Diabetic Patients Without Known Atherosclerosis
In high-risk diabetic patients with no known significant atherosclerosis and no prior heart attack or stroke, evolocumab reduced the composite risk of coronary heart disease death, myocardial infarction, or ischemic stroke by approximately 31% compared with placebo (HR 0.69, 95% CI 0.52–0.91; p = 0.009) over a median follow-up of 4.8 years. This positive result extends across both primary endpoints and includes a signal toward reduced all-cause mortality, supporting a meaningful cardiovascular benefit in this previously understudied group.
What Was Studied
This analysis investigated whether the PCSK9 inhibitor evolocumab, when added to statin therapy, could prevent a first major cardiovascular event in patients who had no established significant atherosclerosis but carried high risk due to diabetes. The question has particular importance because intensive LDL-C–lowering with PCSK9 inhibitors has historically been directed toward patients with documented atherosclerotic disease, leaving uncertain whether similar benefit exists in those without it.
How It Was Studied
VESALIUS-CV was a randomized, double-blind, placebo-controlled trial conducted at 774 sites across 33 countries. This report focuses on a prespecified subgroup of 3,655 patients who had no prior arterial revascularization, no arterial stenosis of 50% or greater, and no coronary artery calcium score at or above 100 Agatston units — all of whom had diabetes and an LDL-C level of at least 90 mg/dL, with no history of myocardial infarction or stroke. Participants were randomized 1:1 to subcutaneous evolocumab 140 mg every two weeks or matching placebo, each added to the highest tolerated statin dose. Enrollment began in June 2019, with a median follow-up of 4.8 years. The subgroup was 57% female with a median age of 65 years.
What Was Observed
- 3-P MACE was substantially reduced with evolocumab. The composite of coronary heart disease death, myocardial infarction, and ischemic stroke occurred in 5.0% of the evolocumab group versus 7.1% of the placebo group by five-year Kaplan-Meier estimate — about a 31% lower risk (HR 0.69, 95% CI 0.52–0.91; p = 0.009), corresponding to an absolute risk difference of 2.1 percentage points (95% CI, 0.4%–3.8%).
- The broader 4-P MACE endpoint showed the same magnitude of benefit. When ischemia-driven arterial revascularization was added to the composite, event rates were 7.6% versus 10.5% — again approximately 31% lower risk in the evolocumab group (HR 0.69, 95% CI 0.55–0.86; p = 0.001), with an absolute difference of 2.9 percentage points (95% CI, 0.9%–4.9%).
- LDL-C lowering was pronounced and sustained. Among participants in the lipid substudy, median LDL-C at 48 weeks was 52 mg/dL in the evolocumab arm compared with 111 mg/dL in the placebo arm — a difference of approximately 59 mg/dL, confirming robust pharmacological separation between groups.
- All-cause mortality trended lower with evolocumab. There were 136 deaths (7.8% five-year estimate) in the evolocumab group versus 172 deaths (10.1%) in the placebo group, representing about a 24% lower risk of death (HR 0.76, 95% CI 0.61–0.95).
Why This Matters
These findings raise the possibility that intensive LDL-C lowering with PCSK9 inhibition may provide meaningful cardiovascular protection even before clinically significant atherosclerosis has developed, at least among high-risk diabetic patients. The consistency of benefit across both primary endpoints and the mortality signal adds credibility to the overall result. If confirmed, this would challenge the assumption that PCSK9 inhibitors should be limited to patients with established atherosclerotic cardiovascular disease.
How to Read This Result
While the trial was large, rigorously conducted, and the subgroup was prespecified, these remain subgroup-level findings from within a broader trial, which carries inherent limitations in statistical power and interpretation, and the results apply specifically to diabetic patients, so caution is warranted before extending conclusions to other populations.
Limitations
This analysis is a prespecified subgroup of the VESALIUS-CV trial rather than the primary trial population, which means it carries the well-recognized limitations of subgroup analyses: reduced statistical power relative to the full trial and the possibility that positive findings reflect chance rather than a true treatment effect. Additionally, because all patients in this subgroup had diabetes, the findings cannot be generalized to individuals without diabetes who also lack significant atherosclerosis, leaving that population without direct evidence from this study.